<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813565</url>
  </required_header>
  <id_info>
    <org_study_id>20130135</org_study_id>
    <nct_id>NCT01813565</nct_id>
  </id_info>
  <brief_title>The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.</brief_title>
  <official_title>The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of additional hyaluronic
      acid/chondroitin sulfate to transurethral resection of bladder ulcer in patient with
      interstitial cystitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, parallel, 6 month period study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No benefit of intravesical instillation of Hyaluronic Acid/Chondroitin Sulfate
  </why_stopped>
  <start_date type="Actual">March 20, 2013</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pain scores on the Visual Analogue Scale</measure>
    <time_frame>1month, 3month, 6month</time_frame>
    <description>Change of pain scores on the Visual Analogue Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of symptom improvement</measure>
    <time_frame>1month, 3month, 6month</time_frame>
    <description>Duration of symptom improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of frequency and urgency on voiding diary</measure>
    <time_frame>1month, 3month, 6month</time_frame>
    <description>Changes of frequency and urgency on voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)</measure>
    <time_frame>1month, 6month</time_frame>
    <description>Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Global Response Assessment (GRA), Patient Global Assessment (PGA) score</measure>
    <time_frame>6month</time_frame>
    <description>Score of Global Response Assessment (GRA), Patient Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse event</measure>
    <time_frame>6month</time_frame>
    <description>Occurrence of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF)</measure>
    <time_frame>1month, 6month</time_frame>
    <description>Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of EQ-5D Health Questionnaire</measure>
    <time_frame>1month, 6month</time_frame>
    <description>Change score of EQ-5D Health Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change score of Brief Pain Inventory-short form (BPI-sf)</measure>
    <time_frame>1month, 6month</time_frame>
    <description>Change score of Brief Pain Inventory-short form (BPI-sf)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Additional instillation of hyaluronic acid/chondroitin sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral resection of bladder ulcer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral resection of bladder ulcer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid/chondroitin sulfate</intervention_name>
    <description>Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder</description>
    <arm_group_label>Additional instillation of hyaluronic acid/chondroitin sulfate</arm_group_label>
    <arm_group_label>Transurethral resection of bladder ulcer</arm_group_label>
    <other_name>Ialuril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. must have experienced bladder pain, urinary urgency and urinary frequency, for at
             least 6 months prior to entry into the study

          2. Pain VAS ≥4

          3. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem ≥ 12( and
             pain ≥2, and nocturia ≥ 2)

          4. PUF score ≥ 13

          5. cystoscopic record within 2 years

          6. Hunner ulcer lesion in cystoscopic finding

        Exclusion Criteria:

          1. Scheduled for or use of intravesical therapy (eg, bladder distention,transurethral
             resection of bladder ulcer, instillation) during or within 6months prior to the study
             and use of pentosan polysulfate sodium within 1 months prior to the study

          2. Patients who are pregnancy or, childbearing age without no contraception

          3. Patients with voided volume &lt;40 or, &gt; 400ml

          4. Patients with microscopic hematuria, (≥1+ in dipstick), If not excluded that no
             evidence of neoplastic tumor examination

          5. Patients with urine culture showing evidence of urinary tract infection 1month prior
             to the study

          6. Accompanied medical problem below

               -  Tuberculosis in urinary system

               -  Bladder cancer, urethral cancer, prostate cancer

               -  Recurrent cystitis

               -  anatomical disorder

          7. Patients had prior surgery (eq, bladder augmentation, cystectomy

          8. Patients with neurologic disorder

          9. Patients with indwelling catheter or intermittent self-catheterization

         10. Patients with psychologic problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung -Soo Choo, profesor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Soo Choo</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

